Text Size

HIV and HCV Intervention In Drug Treatment Settings - 1

This study has been completed.
Sponsor:
Collaborator:
Oregon Health and Science University
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00102349
First received: January 27, 2005
Last updated: April 13, 2010
Last verified: April 2010
History of Changes
  Purpose

The purpose of this study is to test two strategies to reduce the risk of contracting Human Immunodeficiency Virus (HIV) or Hepatitis C Virus (HCV) by reducing risk behaviors in patients undergoing drug detoxification.


Condition Intervention Phase
Behavior Therapy
 Behavioral: Behavior Therapy
 Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Prevention
Official Title: HIV and HCV Intervention in Drug Treatment Settings

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS
U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • HIV/HCV injection risk behaviors

Estimated Enrollment: 706
Study Start Date: November 2004
Study Completion Date: February 2006
Primary Completion Date: February 2006 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Volunteers will be IV drug users already enrolled in drug detoxification treatment.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00102349

Locations
United States, Colorado
Denver Health & Hosp Authority
Denver, Colorado, United States, 80204 4507
Island Grove RTC
Greeley, Colorado, United States, 80631
United States, Massachusetts
SSTAR (Stanley St. Treatment & Resources, Inc)
Fall River, Massachusetts, United States, 02720
United States, Michigan
James Gilmore Jr. Treatment Center
Kalamazoo, Michigan, United States, 49408
United States, Oregon
Willamette Family Treatment Services
Eugene, Oregon, United States, 97402
United States, Rhode Island
SSTAR of Rhode Island - North Kingstown
North Kingstown, Rhode Island, United States, 02852
United States, Washington
Recovery Center King Co.-Kent Detox
Kent, Washington, United States, 98032
Recovery Center King Co.-Seattle Detox
Seattle, Washington, United States, 98144
Sponsors and Collaborators
University of Colorado, Denver
Oregon Health and Science University
Investigators
Principal Investigator: Robert Booth, Ph.D. University of Colorado, Denver
  More Information

No publications provided

Responsible Party: Robert Booth, Ph.D., University of Colorado at Denver
ClinicalTrials.gov Identifier: NCT00102349     History of Changes
Other Study ID Numbers: NIDA-CTN-0017-1
Study First Received: January 27, 2005
Last Updated: April 13, 2010
Health Authority: United States: Federal Government

ClinicalTrials.gov processed this record on June 17, 2013